دورية أكاديمية
أعرض في EDS

Equine peripheral blood CD14 + monocyte-derived macrophage in-vitro characteristics after GM-CSF pretreatment and LPS+IFN-γ or IL-4+IL-10 differentiation.

التفاصيل البيبلوغرافية
العنوان: Equine peripheral blood CD14 + monocyte-derived macrophage in-vitro characteristics after GM-CSF pretreatment and LPS+IFN-γ or IL-4+IL-10 differentiation.
المؤلفون: Bowlby CM; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, United States., Purmessur D; Department of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, United States., Durgam SS; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, United States. Electronic address: durgam.3@osu.edu.
المصدر: Veterinary immunology and immunopathology [Vet Immunol Immunopathol] 2023 Jan; Vol. 255, pp. 110534. Date of Electronic Publication: 2022 Dec 07.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Scientific Country of Publication: Netherlands NLM ID: 8002006 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2534 (Electronic) Linking ISSN: 01652427 NLM ISO Abbreviation: Vet Immunol Immunopathol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] Elsevier Scientific.
مواضيع طبية MeSH: Granulocyte-Macrophage Colony-Stimulating Factor*/pharmacology , Granulocyte-Macrophage Colony-Stimulating Factor*/metabolism , Lipopolysaccharides*/pharmacology, Animals ; Horses ; Interleukin-10/metabolism ; Interleukin-4/metabolism ; Monocytes ; Macrophages/metabolism ; Cell Differentiation ; Interferon-gamma/metabolism ; Cells, Cultured
مستخلص: Macrophages are a heterogeneous population of immune cells that exhibit dynamic plasticity, polarize into inflammatory or regulatory/pro-resolving macrophages, and influence the healing tissue microenvironment. This study evaluated the in-vitro morphological, proliferative, cell surface marker expression and cytokine/soluble factor secretion characteristics of control, GM-CSF pretreated and inflammatory (LPS+IFN-γ) and regulatory (IL-4 + IL-10) differentiated equine CD14 + monocyte-derived macrophages. Phase contrast microscopy demonstrated that LPS+IFN-γ-primed macrophages exhibited a rounded, granular morphology, whereas IL-4 +IL-10-primed macrophages were elongated with a spindle-shaped morphology. GM-CSF enhanced the proliferation rate of monocytes/macrophages during adherent in-vitro culture. Flow cytometry analysis showed that GM-CSF alone and GM-CSF pretreatment with LPS+IFN-γ or IL-4 +IL-10 priming increased CD86 immunopositivity by 2-fold (p = 0.6); and CD206 immunopositivity remained unchanged. GM-CSF pretreatment and subsequent priming with LPS and IFN-γ yielded inflammatory macrophages that secrete significantly increased quantities of IL-1β compared to control (p = 0.012) and IL-4 +IL-10-primed (p = 0.0047) macrophages. GM-CSF pretreatment followed by both LPS + IFN-γ and IL-4 + IL-10 priming significantly increased IL-1Ra secretion by 6-fold (p < 0.05). There were no differences in TGFβ-1 secretion among control, LPS+IFN-γ or IL-4 + IL-10 primed macrophages (p = 0.85). All groups contained an average of 643 ± 51.5 pg/mL of TGFβ1. Among the culture conditions evaluated, IL-4 +IL-10 priming for 24 h after 6 days of adherent culture yielded macrophages that were the least inflammatory compared to GM-CSF pretreated and LPS+IFN-γ or IL-4 +IL-10-primed macrophages. These results provide a basis for subsequent in-vitro and in-vivo studies that investigate macrophage-tissue cell interactions and related biological mechanisms relevant to the field of immunomodulatory approaches for enhancing tissue healing.
Competing Interests: Declaration of Competing Interest The authors do not have any conflicts of interest.
(Copyright © 2022. Published by Elsevier B.V.)
References: J Biol Chem. 2012 Jun 22;287(26):21816-25. (PMID: 22549785)
Clin Transl Immunology. 2016 Nov 02;5(11):e111. (PMID: 27990286)
Front Immunol. 2017 Sep 07;8:1097. (PMID: 28936211)
Sci Rep. 2017 Aug 29;7(1):9801. (PMID: 28851983)
Stem Cell Res Ther. 2015 Apr 16;6:74. (PMID: 25889287)
J Vet Intern Med. 2020 Nov;34(6):2710-2718. (PMID: 33026127)
J Diabetes Sci Technol. 2012 May 01;6(3):534-40. (PMID: 22768883)
Arthritis Rheum. 2012 Apr;64(4):1098-109. (PMID: 22006294)
J Orthop Res. 2014 Jul;32(7):944-51. (PMID: 24700411)
Front Immunol. 2014 Oct 07;5:491. (PMID: 25339958)
Equine Vet J. 2015 Mar;47(2):212-7. (PMID: 24735323)
Thorax. 2001 Sep;56(9):696-702. (PMID: 11514690)
Mar Drugs. 2020 May 27;18(6):. (PMID: 32471037)
Front Vet Sci. 2021 Nov 25;8:759828. (PMID: 34901249)
Biomolecules. 2019 Dec 30;10(1):. (PMID: 31906038)
Curr Protoc. 2022 Mar;2(3):e400. (PMID: 35349226)
PLoS One. 2017 Aug 17;12(8):e0183572. (PMID: 28817687)
F1000Prime Rep. 2014 Mar 03;6:13. (PMID: 24669294)
PLoS One. 2017 Jul 7;12(7):e0181127. (PMID: 28686669)
Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17253-8. (PMID: 24101477)
Exp Mol Pathol. 1994 Oct;61(2):109-18. (PMID: 7859827)
J Immunol. 1988 Jul 1;141(1):139-44. (PMID: 3288696)
Arthritis. 2012;2012:735472. (PMID: 22288012)
Stem Cells Int. 2019 Dec 27;2019:1602751. (PMID: 31949435)
J Immunol. 2008 May 1;180(9):5771-7. (PMID: 18424693)
Immunology. 2006 Apr;117(4):463-73. (PMID: 16556260)
Front Immunol. 2021 Dec 08;12:734322. (PMID: 34956173)
J Ethnopharmacol. 2021 Oct 5;278:114307. (PMID: 34107329)
Semin Immunol. 2021 Apr;54:101523. (PMID: 34776300)
Clin Exp Med. 2014 Aug;14(3):275-83. (PMID: 23824148)
Bone Joint Res. 2019 Nov 02;8(10):481-488. (PMID: 31728188)
Infect Immun. 2014 Oct;82(10):4190-203. (PMID: 25047849)
Equine Vet J. 2013 Mar;45(2):249-53. (PMID: 22994596)
Am J Respir Cell Mol Biol. 2015 Nov;53(5):676-88. (PMID: 25870903)
Oncoimmunology. 2019 Nov 3;9(1):1683347. (PMID: 32002295)
Respir Res. 2018 Sep 24;19(1):186. (PMID: 30249259)
Bone Joint Res. 2012 Nov 01;1(11):297-309. (PMID: 23610661)
Integr Biol (Camb). 2016 Sep 12;8(9):946-55. (PMID: 27492191)
FASEB J. 2019 Dec;33(12):14337-14353. (PMID: 31665925)
FASEB J. 2021 Jun;35(6):e21618. (PMID: 33982337)
FASEB J. 2020 Mar;34(3):4430-4444. (PMID: 32030831)
Vet Rec. 2015 Aug 15;177(7):173-9. (PMID: 26273009)
Nat Rev Immunol. 2013 Jun;13(6):397-411. (PMID: 23702978)
Stem Cell Res Ther. 2016 Jan 22;7:15. (PMID: 26801095)
PLoS One. 2010 Jan 25;5(1):e8852. (PMID: 20111605)
Vet Immunol Immunopathol. 2018 Jan;195:65-71. (PMID: 29249319)
Mol Immunol. 2015 Jul;66(1):97-105. (PMID: 25547716)
J Vet Intern Med. 2000 May-Jun;14(3):258-65. (PMID: 10830538)
Vet Immunol Immunopathol. 2009 Mar 15;128(1-3):16-23. (PMID: 19056130)
BMC Vet Res. 2017 Jan 5;13(1):7. (PMID: 28056978)
Front Immunol. 2014 Oct 17;5:514. (PMID: 25368618)
Immunology. 2013 Aug;139(4):472-83. (PMID: 23461413)
J Orthop Res. 2020 Aug;38(8):1666-1675. (PMID: 32190920)
Blood. 1988 Apr;71(4):997-1002. (PMID: 2833334)
Immunol Lett. 2017 Feb;182:50-56. (PMID: 28063891)
Blood. 1998 May 15;91(10):3892-900. (PMID: 9573027)
Equine Vet J. 2013 Sep;45(5):642-8. (PMID: 23448172)
معلومات مُعتمدة: KL2 TR002734 United States TR NCATS NIH HHS
فهرسة مساهمة: Keywords: Cytokine; Equine; Immunomodulation; Macrophage; Monocyte
المشرفين على المادة: 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
0 (Lipopolysaccharides)
130068-27-8 (Interleukin-10)
207137-56-2 (Interleukin-4)
82115-62-6 (Interferon-gamma)
تواريخ الأحداث: Date Created: 20221211 Date Completed: 20230102 Latest Revision: 20240102
رمز التحديث: 20240102
مُعرف محوري في PubMed: PMC9807231
DOI: 10.1016/j.vetimm.2022.110534
PMID: 36502640
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-2534
DOI:10.1016/j.vetimm.2022.110534